Lbp Am Sa Sells 27,092 Shares of Bruker Co. (NASDAQ:BRKR)

Lbp Am Sa cut its holdings in Bruker Co. (NASDAQ:BRKR) by 42.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 36,770 shares of the medical research company’s stock after selling 27,092 shares during the quarter. Lbp Am Sa’s holdings in Bruker were worth $2,155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC grew its position in shares of Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company’s stock valued at $987,981,000 after purchasing an additional 2,521,904 shares during the period. State Street Corp grew its position in shares of Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company’s stock valued at $250,501,000 after purchasing an additional 318,808 shares during the period. RTW Investments LP grew its position in shares of Bruker by 1.1% in the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company’s stock valued at $240,406,000 after purchasing an additional 37,024 shares during the period. Geode Capital Management LLC grew its position in shares of Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company’s stock valued at $137,702,000 after purchasing an additional 193,580 shares during the period. Finally, Vaughan Nelson Investment Management L.P. grew its position in shares of Bruker by 140.3% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company’s stock valued at $66,930,000 after purchasing an additional 666,617 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Trading Up 2.2 %

NASDAQ BRKR opened at $45.97 on Friday. The company has a market cap of $6.97 billion, a PE ratio of 60.49, a PEG ratio of 2.16 and a beta of 1.18. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15. Bruker Co. has a 12 month low of $44.11 and a 12 month high of $94.86. The stock has a 50 day moving average of $53.66 and a 200-day moving average of $58.40.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, equities research analysts anticipate that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend is Monday, March 17th. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Bank of America boosted their price objective on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Barclays reduced their price target on Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research report on Monday, February 10th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research report on Thursday, December 5th. UBS Group initiated coverage on Bruker in a research report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research report on Monday, February 24th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.